Iain B. Gardner
Certara (United States) · 141 works · 5,268 citations · h-index 36
Top works
- A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups
- Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist
- Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
- Adverse outcome pathways: opportunities, limitations and open questions
- Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
- A Comparison of the Covalent Binding of Clozapine and Olanzapine to Human Neutrophils In Vitro and In Vivo
- Modelling and PBPK Simulation in Drug Discovery
- An Introduction to Drug Disposition: The Basic Principles of Absorption, Distribution, Metabolism, and Excretion
- Zebrafish based assays for the assessment of cardiac, visual and gut function — potential safety screens for early drug discovery
- A Comparison of the Oxidation of Clozapine and Olanzapine to Reactive Metabolites and the Toxicity of these Metabolites to Human Leukocytes
- pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery
- Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling
- Application of PBPK modelling in drug discovery and development at Pfizer
- Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations
- The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore
- A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins
- Immunochemical Detection of Covalently Modified Protein Adducts in Livers of Rats Treated with Methyleugenol
- Excretion and Metabolism of Lersivirine (5-{[3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor, after Administration of [14C]Lersivirine to Healthy Volunteers
- Acute effects of the imidacloprid metabolite desnitro-imidacloprid on human nACh receptors relevant for neuronal signaling
- Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes